• Explore /
  • Poster
  • / Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated <em>BRAF</em> V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.

Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.

Abstract Video & Slides Poster

Authors

Reinhard Dummer

Reinhard Dummer

Universitäts Spital Zürich, Zurich, Switzerland

Reinhard Dummer , Georgina V. Long , Hussein A. Tawbi , Keith Flaherty , Paolo Antonio Ascierto , Paul D. Nathan , Piotr Rutkowski , Oleg Leonov , Mario Mandalà , Paul Lorigan , Pier Francesco Ferrucci , Jean-Jacques Grob , Nicolas Meyer , Helen Gogas , Daniil Stroyakovskiy , Ana Maria Arance , Neha Pakhle , Sorcha Waters , Antoni Ribas , Dirk Schadendorf

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02967692

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9527)

DOI

10.1200/JCO.2022.40.16_suppl.9527

Abstract #

9527

Poster Bd #

120

Abstract Disclosures

Similar Posters

First Author: Dirk Schadendorf

First Author: Dirk Schadendorf

First Author: Paolo Antonio Ascierto

First Author: Nikhil I. Khushalani